Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.
A 73-Year-Old Woman with Relapsed DLBCL
A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.
Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.
Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.
Considering a patient’s relapse and potential response to therapy, Daniel O. Persky, MD, looks forward to the future use of novel therapies in diffuse large B-cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
